Since ERK is located downstream of K-RAS-RAF pathway, both of which are major driving oncogenes mutated in various cancers, and the ERK1/2 inhibitor ulixertinib has been investigated as a cancer agent in phase I dose-escalation and expansion studies [72], ERK biosensors will be beneficial to cancer research. Here, MAPK1 is linked to cancer.